Literature DB >> 17127027

A simple sample preparation with HPLC-UV method for estimation of tiropramide from plasma: application to bioequivalence study.

Khan Imran1, Loya Punnamchand, Saraf Madhusudan Natvarlal.   

Abstract

A simple, rapid and selective method was developed for estimation of tiropramide from human plasma. The method involves extracting the tiropramide with n-hexane using diphenhydramine hydrochloride as internal standard. Chromatographic separation was carried out on a reversed phase C(18) column using mixture of water and acetonitrile as mobile phase with UV detection set at 230 nm. The retention time of internal standard and tiropramide were 5.6+/-0.2 and 8.3+/-0.3 min, respectively. The method was validated and found to be linear in the range of 10-200 ng/ml. The co-efficient of variation for intra-day and inter-day accuracy and precision was less than 12.8%. The mean recovery was found to be 89%. An open, randomized, two-treatment, two period, single dose crossover, bioequivalence study in 12 fasting, healthy, male, volunteers was conducted. After dosing, serial blood samples were collected for the period of 12 h. Various pharmacokinetic parameters including AUC(0-t), AUC(0-infinity), C(max), T(max), T(1/2), and elimination rate constant (K(el)) were determined from plasma concentration of both formulations. Log transformed values were compared by analysis of variance (ANOVA) followed by classical 90% confidence interval for C(max), AUC(0-t) and AUC(0-infinity) and was found to be within the range. These results indicated that the analytical method was linear, precise and accurate. Test and reference formulation were found to be bioequivalent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17127027     DOI: 10.1016/j.jpba.2006.10.001

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal:  Pharmaceutics       Date:  2020-04-18       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.